Browse by category

People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss, according to University College London (UCL) and University of Cambridge researchers. The research led by Dr Marie Spreckley from the University of Cambridge, found a lack of robust evidence surrounding nutritional advice and support and the impact this has on

In 2025, approximately 4.9 million British adults — almost one in ten — are estimated to have recently used, or expressed interest in using, glucagon-like peptide-1 (GLP-1) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist medications to support weight loss. The GLP-1 and GLP-1/GIP medications liraglutide, semaglutide and tirzepatide are licensed for weight loss in the UK but only around 220,000 people will be eligible for treatment with these

A new study co-led by the Southern California Superfund Research and Training Program for PFAS Assessment, Remediation and Prevention (ShARP) Center and the University of Hawai'i has linked certain common "forever chemicals" to a higher risk of liver disease in adolescents. Perfluoroheptanoic acid (PFHpA) These synthetic compounds, known as per- and polyfluoroalkyl substances (PFAS), may as much as triple the chances that adolescents develop a liver condition called metabolic

The FDA has approved Novo Nordisk’s once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the US. The Wegovy pill can be used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off. The pill is also indicated to reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke in adults with

Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition. CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2

Bariatric patients may need closer monitoring of their prescription medications post-surgery to avoid risk of harm, according to researchers at King’s College London. Their study found that bariatric surgery patients face unique risk factors relating to overdose. This is because the surgical changes to their stomach and intestine to reduce food and nutrient absorption, can also affect how they absorb drugs. By examining data from the National Programme of Substance Use Mortal